Northpointe Bancshares, Inc.

NYSE:NPB

Banks - Regional

Financial Services
$14.79 +0.11%

+$0.02 today

Market cap
$511.47M
Beta
0.11
P/E (TTM)
3.1
EPS (TTM)
$5.85
Dividend yield
0.56%
52W Low $12.95High $19.48

Volume 0.33M

Average 0.15M

NPB Pre-Tax Margin

Income before tax as a percentage of revenue.

Northpointe Bancshares, Inc.NYSE: NPB

Pre-Tax Margin · Q1 FY2026 · quarter ended Mar 2026

Pre-tax margin widens to 23.8%

Pre-tax margin was 23.8% in Q1 FY2026, up 1.6 pp from a year earlier. On a trailing-twelve-month basis it was 23.8%, up 4.1 pp year over year. Over 3 fiscal years it widened by 13.0 pp.

Context

  • Pre-tax margin widened in 3 of the last 3 fiscal years.
  • FY2025 was the highest level in the 4 fiscal years shown.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
23.8%-1.2 pp QoQ
Last fiscal yearDec 2025
23.4%+4.8 pp YoY
LTMMar 2026
23.8%+4.1 pp YoY
Pre-Tax Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter+1.6 pp——
1 year+4.8 pp——
3 years+13.0 pp——
5 years——
10 years——

Pre-Tax Margin history

Percent of revenue · from the income statement

Latest · FY2025
23.4%
Year-over-year change
+4.8pp

Pre-Tax Margin vs competitors

How NPB compares with its peers on the latest reported figures

  • NPB's LTM Mar 2026 pre-tax margin of 23.8% is the highest of the 4 companies compared; the peer median is -42.4%.
  • Its year-over-year change of +4.1 pp is the 3rd highest of 4, against a peer median of +7.3 pp.
  • Over three fiscal years its change of +13.0 pp compares with a peer median of +167.4 pp.
NPB Competitors Peer median
Pre-Tax Margin for NPB and competitors
Company Period LTM level YoY 3-year change
NPBNorthpointe Bancshares, Inc.LTM Mar 202623.8% +4.1 pp+13.0 pp
LEGNLegend Biotech CorporationLTM Sep 20262.4% +26.8 pp+353.5 pp
ZLABZai Lab LimitedLTM Jun 2026-42.4% +7.3 pp+167.4 pp
CCCCC4 Therapeutics, Inc.LTM Mar 2026-297.4% -38.1 pp+120.4 pp
ERASErasca, Inc.FY2025— ——
CGEMCullinan Therapeutics, Inc.FY2025— ——
ALXOALX Oncology Holdings Inc.FY2025— ——
Peer median (excluding NPB) -42.4%+7.3 pp+167.4 pp

Competitors are the stored peer set for NPB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue2.17M324.24M362.45M390.46M471.18M
Cost of Revenue1.14M68.9M164.68M202.99M231.56M
Gross Profit1.02M255.34M197.77M187.47M239.62M
Gross Margin47.3%78.7%54.6%48.0%50.9%
Research & Development29.88M0000
Selling, General & Admin22.17M159.88M104.29M77.79M93.62M
Operating Expenses52.05M221.65M153.08M114.59M129.23M
Depreciation & Amortization840.94K4.02M4.02M3.8M3.07M
EBITDA(56.67M)37.71M48.7M76.68M113.47M
EBITDA Margin-2613.5%11.6%13.4%19.6%24.1%
Operating Income(51.03M)33.69M44.69M72.88M110.39M
Operating Margin-2353.1%10.4%12.3%18.7%23.4%
Interest Income525.54K166.12M267.38M317.53M380.2M
Interest Expense066.69M166.16M203.32M229.47M
Other Income / Expenses(6.49M)0000
Income Before Tax(57.52M)33.69M44.69M72.88M110.39M
Pre-Tax Margin-2652.3%10.4%12.3%18.7%23.4%
Income Tax Expense(77.7K)10.46M10.93M17.72M26.98M
Net Income(57.44M)23.24M33.76M55.16M83.41M
Net Margin-2648.7%7.2%9.3%14.1%17.7%
EPS (Basic)(1.74)0.921.613.154.92
EPS (Diluted)(1.74)0.921.613.154.85
Weighted Avg Shares33.03M14.92M14.92M14.92M14.54M
Weighted Avg Shares (Diluted)33.03M14.92M14.92M14.92M14.72M

Northpointe Bancshares, Inc.

NYSE:NPB

Intrinsic Alpha fair value

Locked

Current Price

$14.79

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.